PFE - Pfizer's Respiratory Syncytial Virus Vaccine Maintains Staying Power In Older Adults Through 2nd RSV season Study Finds | Benzinga
Thursday, Pfizer Inc (NYSE:PFE) announced top-line Abrysvo vaccine efficacy and safety data for respiratory syncytial virus (RSV) in adults 60 years of age and older following a second season in the Northern and Southern Hemispheres from the ongoing pivotal Phase 3 trial RENOIR.
Vaccine efficacy against RSV-associated lower respiratory tract disease (LRTD), defined by three or more symptoms, after disease surveillance in season two was 77.8%.
Related Content: GSK’s Competitive Edge, Surpasses Pfizer in Respiratory Syncytial Virus Vaccine Sales.
Vaccine efficacy following season one was 88.9%, demonstrating durable efficacy after ...